BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment

Phase

N/A

Condition

Asthma

Treatment

N/A

Clinical Study ID

NCT03361111

Dep. of Pneum. and Allerg.

Ages 18-70
All Genders

Study Summary

Eosinophil infiltration and degranulation in airways has been implicated in the pathology of asthma. Periostin is considered to be a marker of eosinophilic inflammation and is one of the highly expressed genes in epithelial cells and lung fibroblasts in asthma. Omalizumab is approved as add-on therapy in the treatment of severe allergic asthma. The aim of the study is to assess inflammatory biomarkers including: blood and sputum eosinophilia, periostin and IL-6 as long-term clinical outcomes of omalizumab therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

positive history of atopy
serum total IgE level between 30 and 700 IU/ml
body weight not more than 150 kg
high dose of ICS and LABA
a documented history of 2-6 exacerbations requiring treatment with systemiccorticosteroids ( with >15 mg/day prednisone or other medications at similar dose, forat least 3 days).

Exclusion

Exclusion Criteria:

smoking
pregnancy

Study Design

April 04, 2013

December 30, 2018

Study Description

Anti-IgE (omalizumab) has been shown to be an effective add-on therapy for patients with allergic severe asthma. In this observational study patients aged over 18 year with uncontrolled severe persistent asthma are selected for add-on therapy with omalizumab. Patients were on high dose of ICS and had a documented history of 2-6 exacerbations requiring treatment with systemic corticosteroids ( with >15 mg/day prednisone or other medications at similar dose, for at least 3 days). The individual dose and frequency of omalizumab administration is assessed from the dosing table. Lung function tests and asthma questionnaires (ACQ, AQLQ and RQLQ) are used in the aim of assessing clinical improvement after omalizumab treatment. Induced sputum (IS) and exhaled breath condensate (EBC) are used as a simple non-invasive methods for monitoring cellular and biochemical changes in the airways. Total blood eosinophil count, IS cytology, IS and EBC periostin and IL-6 concentrations are measured. Analyses are performed at entry and after 16, 52 and 104,156 weeks of omalizumab treatment.

Connect with a study center

Joanna Hermanowicz-Salamon
Warsaw, 00-707
Poland
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.